Skip to main
SEPN
SEPN logo

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna Inc's enterprise value stands at approximately $430 million, suggesting significant growth potential, with estimates of 8-10 times upside to the current share price should its partnership with Novopro yield successful results. The management's confidence in leveraging prior experience with SEP-786 for improved efficiency in Phase 1 trials, combined with preclinical findings indicating a longer half-life for SEP-631, positions the company favorably for advancing its drug pipeline. Additionally, if SEP-631 can match the efficacy of Xolair, it could potentially reach blockbuster status, aligning with the company's focus on innovative treatments in endocrinology, immunology, and metabolic disease.

Bears say

Septerna Inc faces several fundamental risks that could negatively impact its stock performance, including potential delays in clinical development and setbacks in trials for its drug candidates, such as SEP-631. Additionally, the company's partnership with Novo Nordisk presents risks that could hinder progress and market approval for its therapies. Furthermore, concerns regarding lower-than-expected market penetration rates and long-term dilution risks add to an already challenging outlook, compounded by a recent transaction in the obesity sector that highlights a potential valuation gap.

Septerna Inc (SEPN) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Buy based on their latest research and market trends.

According to 4 analysts, Septerna Inc (SEPN) has a Buy consensus rating as of Dec 19, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.